Paid Clinical Trials for Acute Lymphocytic Leukemia

Showing all 7 results

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

by CTG

in Myelodysplastic Syndromes, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, aGVHD

Other

Ohio

Deadline:

02/25/2030

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

by CTG

in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia

Other

Texas

Deadline:

02/01/2036

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

by CTG

in Chronic Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Biphenotypic/Undifferentiated Leukemia, Acute Myeloid Leukemia

Other

Minnesota

Deadline:

12/01/2026

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

by CTG

in Acute Lymphocytic Leukemia

Other

Kansas

Deadline:

05/01/2027

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

by CTG

in Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia

Other

Missouri

Deadline:

05/31/2030

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

by CTG

in Lymphoma, Acute Lymphocytic Leukemia

Other

New York

Deadline:

09/01/2026

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

by CTG

in Acute Lymphocytic Leukemia, All, Leukemia, Hematologic Malignancy, Lymphoma

Other

Ohio

Deadline:

12/01/2027

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Acute Lymphocytic Leukemia

Filter Results:

Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood

Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps